ZA201000432B - 6-(pyrrolopyridinyl)pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and aids - Google Patents
6-(pyrrolopyridinyl)pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and aidsInfo
- Publication number
- ZA201000432B ZA201000432B ZA201000432A ZA201000432A ZA201000432B ZA 201000432 B ZA201000432 B ZA 201000432B ZA 201000432 A ZA201000432 A ZA 201000432A ZA 201000432 A ZA201000432 A ZA 201000432A ZA 201000432 B ZA201000432 B ZA 201000432B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyrrolopyridinyl
- pyrimidin
- aids
- cancer
- treatment
- Prior art date
Links
- REPODGYKGOPEIK-UHFFFAOYSA-N 4-(1h-pyrrolo[3,2-b]pyridin-2-yl)pyrimidin-2-amine Chemical class NC1=NC=CC(C=2NC3=CC=CN=C3C=2)=N1 REPODGYKGOPEIK-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007028515A DE102007028515A1 (de) | 2007-06-21 | 2007-06-21 | 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201000432B true ZA201000432B (en) | 2010-10-27 |
Family
ID=39916277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA201000432A ZA201000432B (en) | 2007-06-21 | 2010-01-20 | 6-(pyrrolopyridinyl)pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and aids |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8546390B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2155745B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5411849B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20100040862A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101679425B (cg-RX-API-DMAC7.html) |
| AR (1) | AR067081A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008266584B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0812944A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2691223C (cg-RX-API-DMAC7.html) |
| DE (1) | DE102007028515A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA016160B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2533873T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL202828A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009013341A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008155000A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201000432B (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2683398A1 (en) * | 2007-04-10 | 2008-10-16 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| DE102008031517A1 (de) * | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
| DE102009019962A1 (de) * | 2009-05-05 | 2010-11-11 | Merck Patent Gmbh | 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate |
| DE102009060174A1 (de) | 2009-12-23 | 2011-06-30 | Merck Patent GmbH, 64293 | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
| DE102009060175A1 (de) | 2009-12-23 | 2011-06-30 | Merck Patent GmbH, 64293 | Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen |
| DE102010050558A1 (de) * | 2010-11-05 | 2012-05-10 | Merck Patent Gmbh | 1H-Pyrrolo[2,3-b]pyridinderivate |
| DE102010053347A1 (de) | 2010-12-03 | 2012-06-06 | Merck Patent Gmbh | 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren |
| DE102011009961A1 (de) | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
| EP3255049A1 (en) | 2012-06-29 | 2017-12-13 | Pfizer Inc | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
| WO2014111496A1 (en) * | 2013-01-18 | 2014-07-24 | F. Hoffmann-La Roche Ag | 3-substituted pyrazoles and use as dlk inhibitors |
| RU2680100C9 (ru) * | 2013-03-15 | 2019-04-18 | Плексксикон Инк. | Гетероциклические соединения и их применения |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| JP6487921B2 (ja) | 2013-12-17 | 2019-03-20 | ファイザー・インク | ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン |
| KR102161364B1 (ko) | 2015-09-14 | 2020-09-29 | 화이자 인코포레이티드 | LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체 |
| WO2017161004A1 (en) * | 2016-03-15 | 2017-09-21 | University Of South Florida | PKCδ INHIBITOR FORMULATIONS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS |
| RU2738646C2 (ru) | 2016-04-01 | 2020-12-15 | РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС | Модуляторы эстрогеновых рецепторов |
| JP7675519B2 (ja) | 2017-10-13 | 2025-05-13 | オプナ バイオ ソシエテ アノニム | キナーゼを調節するための化合物の固体形態 |
| AU2020271836B2 (en) * | 2019-04-09 | 2025-11-13 | Opna Bio SA | Condensed azines for EP300 or CBP modulation and indications therefor |
| KR20220044528A (ko) | 2019-08-06 | 2022-04-08 | 리커리엄 아이피 홀딩스, 엘엘씨 | 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제 |
| CN118772140A (zh) * | 2023-04-07 | 2024-10-15 | 四川大学 | 一类化合物及其在治疗hDHODH介导的疾病中的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
| US6265434B1 (en) | 1999-04-06 | 2001-07-24 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| PL2332940T3 (pl) * | 2004-03-30 | 2013-03-29 | Vertex Pharma | Azaindole użyteczne jako inhibitory JAK i innych kinaz białkowych |
| US20080153869A1 (en) * | 2004-06-14 | 2008-06-26 | Bressi Jerome C | Kinase Inhibitors |
| WO2006015123A1 (en) * | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| EP1828180A4 (en) * | 2004-12-08 | 2010-09-15 | Glaxosmithkline Llc | 1H-pyrrolo [2,3-BETA] PYRIDINE |
| CN101218241B (zh) * | 2005-05-16 | 2011-02-16 | Irm责任有限公司 | 用作蛋白激酶抑制剂的吡咯并吡啶衍生物 |
| DE102006012617A1 (de) * | 2006-03-20 | 2007-09-27 | Merck Patent Gmbh | 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
-
2007
- 2007-06-21 DE DE102007028515A patent/DE102007028515A1/de not_active Withdrawn
-
2008
- 2008-05-23 JP JP2010512544A patent/JP5411849B2/ja not_active Expired - Fee Related
- 2008-05-23 EA EA201000004A patent/EA016160B1/ru not_active IP Right Cessation
- 2008-05-23 EP EP08758743.2A patent/EP2155745B1/de not_active Not-in-force
- 2008-05-23 ES ES08758743.2T patent/ES2533873T3/es active Active
- 2008-05-23 CN CN2008800197101A patent/CN101679425B/zh not_active Expired - Fee Related
- 2008-05-23 AU AU2008266584A patent/AU2008266584B2/en not_active Ceased
- 2008-05-23 US US12/664,791 patent/US8546390B2/en not_active Expired - Fee Related
- 2008-05-23 BR BRPI0812944-4A2A patent/BRPI0812944A2/pt not_active IP Right Cessation
- 2008-05-23 WO PCT/EP2008/004151 patent/WO2008155000A1/de not_active Ceased
- 2008-05-23 KR KR1020107001385A patent/KR20100040862A/ko not_active Withdrawn
- 2008-05-23 CA CA2691223A patent/CA2691223C/en not_active Expired - Fee Related
- 2008-05-23 MX MX2009013341A patent/MX2009013341A/es not_active Application Discontinuation
- 2008-06-20 AR ARP080102634A patent/AR067081A1/es unknown
-
2009
- 2009-12-17 IL IL202828A patent/IL202828A0/en unknown
-
2010
- 2010-01-20 ZA ZA201000432A patent/ZA201000432B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008266584B2 (en) | 2013-04-04 |
| CA2691223A1 (en) | 2008-12-24 |
| CN101679425B (zh) | 2013-11-06 |
| CA2691223C (en) | 2015-12-01 |
| EP2155745A1 (de) | 2010-02-24 |
| WO2008155000A1 (de) | 2008-12-24 |
| MX2009013341A (es) | 2010-01-18 |
| BRPI0812944A2 (pt) | 2014-12-16 |
| JP5411849B2 (ja) | 2014-02-12 |
| ES2533873T3 (es) | 2015-04-15 |
| US20110082140A1 (en) | 2011-04-07 |
| EP2155745B1 (de) | 2015-01-28 |
| EA201000004A1 (ru) | 2010-06-30 |
| EA016160B1 (ru) | 2012-02-28 |
| DE102007028515A1 (de) | 2008-12-24 |
| AU2008266584A1 (en) | 2008-12-24 |
| CN101679425A (zh) | 2010-03-24 |
| US8546390B2 (en) | 2013-10-01 |
| KR20100040862A (ko) | 2010-04-21 |
| JP2010530376A (ja) | 2010-09-09 |
| AR067081A1 (es) | 2009-09-30 |
| IL202828A0 (en) | 2010-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201000432B (en) | 6-(pyrrolopyridinyl)pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and aids | |
| IL195731A0 (en) | Pyrimidine derivatives useful in the treatment of cancer | |
| ZA201000075B (en) | Purin derivatives for use in the treatment of fab-related diseases | |
| AP2960A (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
| ZA201202384B (en) | Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer | |
| IL210802A0 (en) | Purin derivatives for use in the treatment of fab-related diseases | |
| ZA201109384B (en) | Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases | |
| IL213070A0 (en) | Methods for the treatment of infections and tumors | |
| IL192763A (en) | History of pyrimidine, preparations containing them and used in the preparation of cancer drugs | |
| ZA201000106B (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| ZA201000087B (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| PL2101731T3 (pl) | Endoksyfen do zastosowania w leczeniu nowotworu | |
| IL201449A0 (en) | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases | |
| ZA201003425B (en) | 5-cyano-thienopyridines for the treatment of tumors | |
| IL200966A0 (en) | Tetrahydroquinoline derivatives and the use thereof for the treatment of cancer | |
| IL206189A (en) | Compounds for use in cancer treatment | |
| IL187792A0 (en) | 4-anilino-3-quinolinecarbonitriles for the treatment of cancer | |
| IL226363A0 (en) | Compounds and methods for treating cancer | |
| GB0517387D0 (en) | Combinations for the treatment of cancer | |
| ZA200805522B (en) | Dioxoiane dérivates for the treatment of cancer | |
| ZA200810524B (en) | Pyrimidine derivatives useful in the treatment of cancer | |
| EP2231684A4 (en) | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | |
| GB0700281D0 (en) | Methods and Means for the Treatment of Cancer | |
| GB0517386D0 (en) | Combinations for the treatment of cancer | |
| HK1170238A (en) | Indolyl-substituted pyrazino-quinolines and their use for the treatment of cancer |